Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opening Session Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Jan
05
Today In Oncology
Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma
Curative Treatment After First-Line Immunotherapy Improves Survival in HCC
Perioperative Camrelizumab Plus Rivoceranib vs Surgery Alone in Hepatocellular Carcinoma
Which First-Line Systemic Therapy Balances Survival and Quality of Life in Advanced Hepatocellular Carcinoma?
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo